Pfizer Inc. has reported strong topline results from its phase 3 MagnetisMM-5 study, signaling a potential shift in myeloma treatment for patients with relapsed or refractory disease.
The trial showed that Elrexfio significantly improved progression-free survival (PFS) compared to the current standard regimen of daratumumab, pomalidomide, and dexamethasone.
The results met the study’s primary endpoint, with most patients on Elrexfio remaining progression-free. The benefit also surpassed the trial’s pre-set threshold for efficacy at interim analysis. Safety and tolerability remained consistent with what has been seen in earlier studies, with no new concerns reported.
Also Read: Digital Health & E-Pharmacy: Reimagining Access, Trust & Care
This update adds momentum to efforts aimed at improving myeloma treatment earlier in the disease course. While overall survival data is still being tracked and not yet mature, Pfizer plans to share detailed findings with global health authorities and present them at a future medical congress.
Multiple Myeloma continues to be a challenging and incurable cancer affecting plasma cells in the bone marrow. It is the second most common blood cancer worldwide, with more than 187,000 new cases each year. Despite advances, most patients relapse, often requiring multiple lines of therapy, and about 40% do not survive beyond five years. The disease also takes a toll on daily life, causing fatigue, bone pain, and increased risk of infections.
“Effective intervention earlier in the course of disease represents a critical opportunity to improve outcomes for people living with multiple myeloma,” said Jeff Legos, chief oncology officer, Pfizer.
Elrexfio is a bispecific antibody that targets BCMA on cancer cells and CD3 on T cells, helping the immune system attack myeloma cells. The ongoing MagnetisMM program continues to explore its use alone and in combination across different stages of treatment.
.jpg)
.jpg)
